Selected research
Industry Research
Cell Line Development CDMO Industry Research Report 2026
Market perspective
The global Cell Line Development CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cell Line Development CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cell Line Development CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cell Line Development CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cell Line Development CDMO include Lonza, Samsung Biologics, AGC Biologics, ProBio CDMO, Creative Biolabs, ProBioGen, InvivoGen, Eurofins Discovery and Innoprot, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cell Line Development CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cell Line Development CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cell Line Development CDMO Market by Company
Lonza
Samsung Biologics
AGC Biologics
ProBio CDMO
Creative Biolabs
ProBioGen
InvivoGen
Eurofins Discovery
Innoprot
AcceGen
WuXi Biologics
GenScript
Pharmaron
Bio-Inno
Dingkang Biotech
FUJIFILM
JCR Pharmaceuticals
Sartorius
Oxford BioMedica
Cobra Biologics
Evotec
Catalent
Thermo Fisher Scientific
Cytiva
Charles River Laboratories
Abzena
Shilpa Biologicals
Teijin
Cell Line Development CDMO Segment by Type
CHO Cell Line
HEK293 Cell Line
Others
Cell Line Development CDMO Segment by Application
Monoclonal Antibodies
Bispecific/Multispecific Antibodies
Recombinant Proteins/Enzymes
Gene Therapy Vectors
Viral Vaccines
Others
Cell Line Development CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Line Development CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell Line Development CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Line Development CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cell Line Development CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Cell Line Development CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global Cell Line Development CDMO Revenue Market Share by Type (2021-2026)
Table 7. Global Cell Line Development CDMO Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global Cell Line Development CDMO Revenue Market Share by Type (2027-2032)
Table 9. Global Cell Line Development CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global Cell Line Development CDMO Revenue Market Share by Application (2021-2026)
Table 11. Global Cell Line Development CDMO Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global Cell Line Development CDMO Revenue Market Share by Application (2027-2032)
Table 13. Global Cell Line Development CDMO Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global Cell Line Development CDMO Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global Cell Line Development CDMO Market Share by Region (2021-2026)
Table 16. Global Cell Line Development CDMO Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global Cell Line Development CDMO Market Share by Region (2027-2032)
Table 18. Cell Line Development CDMO Industry Trends
Table 19. Cell Line Development CDMO Industry Drivers
Table 20. Cell Line Development CDMO Industry Opportunities and Challenges
Table 21. Cell Line Development CDMO Market Restraints
Table 22. Global Top Cell Line Development CDMO Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global Cell Line Development CDMO Revenue Market Share by Players (2021-2026)
Table 24. Global Cell Line Development CDMO Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of Cell Line Development CDMO, Headquarters and Area Served
Table 26. Global Cell Line Development CDMO Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Cell Line Development CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America Cell Line Development CDMO Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America Cell Line Development CDMO Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe Cell Line Development CDMO Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe Cell Line Development CDMO Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific Cell Line Development CDMO Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific Cell Line Development CDMO Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America Cell Line Development CDMO Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America Cell Line Development CDMO Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa Cell Line Development CDMO Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Cell Line Development CDMO Market Size by Country (2027-2032) & (US$ Million)
Table 45. Lonza Company Information
Table 46. Lonza Business Overview
Table 47. Lonza Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 48. Lonza Cell Line Development CDMO Product Portfolio
Table 49. Lonza Recent Developments
Table 50. Samsung Biologics Company Information
Table 51. Samsung Biologics Business Overview
Table 52. Samsung Biologics Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 53. Samsung Biologics Cell Line Development CDMO Product Portfolio
Table 54. Samsung Biologics Recent Developments
Table 55. AGC Biologics Company Information
Table 56. AGC Biologics Business Overview
Table 57. AGC Biologics Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 58. AGC Biologics Cell Line Development CDMO Product Portfolio
Table 59. AGC Biologics Recent Developments
Table 60. ProBio CDMO Company Information
Table 61. ProBio CDMO Business Overview
Table 62. ProBio CDMO Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 63. ProBio CDMO Cell Line Development CDMO Product Portfolio
Table 64. ProBio CDMO Recent Developments
Table 65. Creative Biolabs Company Information
Table 66. Creative Biolabs Business Overview
Table 67. Creative Biolabs Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 68. Creative Biolabs Cell Line Development CDMO Product Portfolio
Table 69. Creative Biolabs Recent Developments
Table 70. ProBioGen Company Information
Table 71. ProBioGen Business Overview
Table 72. ProBioGen Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 73. ProBioGen Cell Line Development CDMO Product Portfolio
Table 74. ProBioGen Recent Developments
Table 75. InvivoGen Company Information
Table 76. InvivoGen Business Overview
Table 77. InvivoGen Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 78. InvivoGen Cell Line Development CDMO Product Portfolio
Table 79. InvivoGen Recent Developments
Table 80. Eurofins Discovery Company Information
Table 81. Eurofins Discovery Business Overview
Table 82. Eurofins Discovery Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 83. Eurofins Discovery Cell Line Development CDMO Product Portfolio
Table 84. Eurofins Discovery Recent Developments
Table 85. Innoprot Company Information
Table 86. Innoprot Business Overview
Table 87. Innoprot Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 88. Innoprot Cell Line Development CDMO Product Portfolio
Table 89. Innoprot Recent Developments
Table 90. AcceGen Company Information
Table 91. AcceGen Business Overview
Table 92. AcceGen Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 93. AcceGen Cell Line Development CDMO Product Portfolio
Table 94. AcceGen Recent Developments
Table 95. WuXi Biologics Company Information
Table 96. WuXi Biologics Business Overview
Table 97. WuXi Biologics Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 98. WuXi Biologics Cell Line Development CDMO Product Portfolio
Table 99. WuXi Biologics Recent Developments
Table 100. GenScript Company Information
Table 101. GenScript Business Overview
Table 102. GenScript Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 103. GenScript Cell Line Development CDMO Product Portfolio
Table 104. GenScript Recent Developments
Table 105. Pharmaron Company Information
Table 106. Pharmaron Business Overview
Table 107. Pharmaron Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 108. Pharmaron Cell Line Development CDMO Product Portfolio
Table 109. Pharmaron Recent Developments
Table 110. Bio-Inno Company Information
Table 111. Bio-Inno Business Overview
Table 112. Bio-Inno Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 113. Bio-Inno Cell Line Development CDMO Product Portfolio
Table 114. Bio-Inno Recent Developments
Table 115. Dingkang Biotech Company Information
Table 116. Dingkang Biotech Business Overview
Table 117. Dingkang Biotech Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 118. Dingkang Biotech Cell Line Development CDMO Product Portfolio
Table 119. Dingkang Biotech Recent Developments
Table 120. FUJIFILM Company Information
Table 121. FUJIFILM Business Overview
Table 122. FUJIFILM Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 123. FUJIFILM Cell Line Development CDMO Product Portfolio
Table 124. FUJIFILM Recent Developments
Table 125. JCR Pharmaceuticals Company Information
Table 126. JCR Pharmaceuticals Business Overview
Table 127. JCR Pharmaceuticals Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 128. JCR Pharmaceuticals Cell Line Development CDMO Product Portfolio
Table 129. JCR Pharmaceuticals Recent Developments
Table 130. Sartorius Company Information
Table 131. Sartorius Business Overview
Table 132. Sartorius Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 133. Sartorius Cell Line Development CDMO Product Portfolio
Table 134. Sartorius Recent Developments
Table 135. Oxford BioMedica Company Information
Table 136. Oxford BioMedica Business Overview
Table 137. Oxford BioMedica Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 138. Oxford BioMedica Cell Line Development CDMO Product Portfolio
Table 139. Oxford BioMedica Recent Developments
Table 140. Cobra Biologics Company Information
Table 141. Cobra Biologics Business Overview
Table 142. Cobra Biologics Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 143. Cobra Biologics Cell Line Development CDMO Product Portfolio
Table 144. Cobra Biologics Recent Developments
Table 145. Evotec Company Information
Table 146. Evotec Business Overview
Table 147. Evotec Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 148. Evotec Cell Line Development CDMO Product Portfolio
Table 149. Evotec Recent Developments
Table 150. Catalent Company Information
Table 151. Catalent Business Overview
Table 152. Catalent Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 153. Catalent Cell Line Development CDMO Product Portfolio
Table 154. Catalent Recent Developments
Table 155. Thermo Fisher Scientific Company Information
Table 156. Thermo Fisher Scientific Business Overview
Table 157. Thermo Fisher Scientific Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 158. Thermo Fisher Scientific Cell Line Development CDMO Product Portfolio
Table 159. Thermo Fisher Scientific Recent Developments
Table 160. Cytiva Company Information
Table 161. Cytiva Business Overview
Table 162. Cytiva Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 163. Cytiva Cell Line Development CDMO Product Portfolio
Table 164. Cytiva Recent Developments
Table 165. Charles River Laboratories Company Information
Table 166. Charles River Laboratories Business Overview
Table 167. Charles River Laboratories Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 168. Charles River Laboratories Cell Line Development CDMO Product Portfolio
Table 169. Charles River Laboratories Recent Developments
Table 170. Abzena Company Information
Table 171. Abzena Business Overview
Table 172. Abzena Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 173. Abzena Cell Line Development CDMO Product Portfolio
Table 174. Abzena Recent Developments
Table 175. Shilpa Biologicals Company Information
Table 176. Shilpa Biologicals Business Overview
Table 177. Shilpa Biologicals Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 178. Shilpa Biologicals Cell Line Development CDMO Product Portfolio
Table 179. Shilpa Biologicals Recent Developments
Table 180. Teijin Company Information
Table 181. Teijin Business Overview
Table 182. Teijin Revenue in Cell Line Development CDMO Business (2021-2026) & (US$ Million)
Table 183. Teijin Cell Line Development CDMO Product Portfolio
Table 184. Teijin Recent Developments
Table 185. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Cell Line Development CDMO Product Image
Figure 5. Global Cell Line Development CDMO Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global Cell Line Development CDMO Market Share by Type: 2025 VS 2032
Figure 7. CHO Cell Line Product
Figure 8. HEK293 Cell Line Product
Figure 9. Others Product
Figure 10. Global Cell Line Development CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 11. Global Cell Line Development CDMO Market Share by Application: 2025 VS 2032
Figure 12. Monoclonal Antibodies Product
Figure 13. Bispecific/Multispecific Antibodies Product
Figure 14. Recombinant Proteins/Enzymes Product
Figure 15. Gene Therapy Vectors Product
Figure 16. Viral Vaccines Product
Figure 17. Others Product
Figure 18. Global Cell Line Development CDMO Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 19. Global Cell Line Development CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 20. Global Cell Line Development CDMO Market Share by Region: 2025 VS 2032
Figure 21. Global Cell Line Development CDMO Market Share by Players in 2025
Figure 22. Global Cell Line Development CDMO Manufacturers Established Date
Figure 23. Global Top 5 and 10 Cell Line Development CDMO Players Market Share by Revenue in 2025
Figure 24. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 25. North America Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 26. North America Cell Line Development CDMO Market Share by Country (2021-2032)
Figure 27. United States Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 28. Canada Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 29. Mexico Cell Line Development CDMO Market Share by Country (2021-2032)
Figure 30. Europe Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. Europe Cell Line Development CDMO Market Share by Country (2021-2032)
Figure 32. Germany Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. France Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 34. U.K. Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 35. Italy Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. Spain Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. Russia Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 38. Netherlands Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 39. Nordic Countries Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 40. Asia-Pacific Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. Asia-Pacific Cell Line Development CDMO Market Share by Country (2021-2032)
Figure 42. China Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 43. Japan Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 44. South Korea Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 45. India Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. India Cell Line Development CDMO Market Share by Country (2021-2032)
Figure 47. Australia Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 48. China Taiwan Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 49. Southeast Asia Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 50. South America Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. South America Cell Line Development CDMO Market Share by Country (2021-2032)
Figure 52. Brazil Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. Argentina Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 54. Chile Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 55. Colombia Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 56. Peru Cell Line Development CDMO Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 57. Lonza Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 58. Samsung Biologics Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 59. AGC Biologics Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 60. ProBio CDMO Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 61. Creative Biolabs Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 62. ProBioGen Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 63. InvivoGen Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 64. Eurofins Discovery Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 65. Innoprot Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 66. AcceGen Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 67. WuXi Biologics Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 68. GenScript Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 69. Pharmaron Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 70. Bio-Inno Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 71. Dingkang Biotech Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 72. FUJIFILM Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 73. JCR Pharmaceuticals Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 74. Sartorius Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 75. Oxford BioMedica Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 76. Cobra Biologics Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 77. Evotec Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 78. Catalent Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 79. Thermo Fisher Scientific Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 80. Cytiva Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 81. Charles River Laboratories Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 82. Abzena Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 83. Shilpa Biologicals Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Figure 84. Teijin Revenue Growth Rate in Cell Line Development CDMO Business (2021-2026)
Scope & coverage.
Types
- CHO Cell Line
- HEK293 Cell Line
- Others
Applications
- Monoclonal Antibodies
- Bispecific/Multispecific Antibodies
- Recombinant Proteins/Enzymes
- Gene Therapy Vectors
- Viral Vaccines
- Others
Companies covered
- Lonza
- Samsung Biologics
- AGC Biologics
- ProBio CDMO
- Creative Biolabs
- ProBioGen
- InvivoGen
- Eurofins Discovery
- Innoprot
- AcceGen
- WuXi Biologics
- GenScript
- Pharmaron
- Bio-Inno
- Dingkang Biotech
- FUJIFILM
- JCR Pharmaceuticals
- Sartorius
- Oxford BioMedica
- Cobra Biologics
- Evotec
- Catalent
- Thermo Fisher Scientific
- Cytiva
- Charles River Laboratories
- Abzena
- Shilpa Biologicals
- Teijin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cell Line Development CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CHO Cell Line
- 2.2.3 HEK293 Cell Line
- 2.2.4 Others
- 2.3 Cell Line Development CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Monoclonal Antibodies
- 2.3.3 Bispecific/Multispecific Antibodies
- 2.3.4 Recombinant Proteins/Enzymes
- 2.3.5 Gene Therapy Vectors
- 2.3.6 Viral Vaccines
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Cell Line Development CDMO Breakdown Data by Type
- 3.1 Global Cell Line Development CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Cell Line Development CDMO Forecasted Market Size by Type (2027-2032)
4 Cell Line Development CDMO Breakdown Data by Application
- 4.1 Global Cell Line Development CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Cell Line Development CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cell Line Development CDMO Market Perspective (2021-2032)
- 5.2 Global Cell Line Development CDMO Growth Trends by Region
- 5.2.1 Global Cell Line Development CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cell Line Development CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Cell Line Development CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Cell Line Development CDMO Market Dynamics
- 5.3.1 Cell Line Development CDMO Industry Trends
- 5.3.2 Cell Line Development CDMO Market Drivers
- 5.3.3 Cell Line Development CDMO Market Challenges
- 5.3.4 Cell Line Development CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cell Line Development CDMO Players by Revenue
- 6.1.1 Global Top Cell Line Development CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Cell Line Development CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Cell Line Development CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cell Line Development CDMO Head Office and Area Served
- 6.4 Global Cell Line Development CDMO Players, Product Type & Application
- 6.5 Global Cell Line Development CDMO Manufacturers Established Date
- 6.6 Global Cell Line Development CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cell Line Development CDMO Market Size (2021-2032)
- 7.2 North America Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cell Line Development CDMO Market Size by Country (2021-2026)
- 7.4 North America Cell Line Development CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cell Line Development CDMO Market Size (2021-2032)
- 8.2 Europe Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cell Line Development CDMO Market Size by Country (2021-2026)
- 8.4 Europe Cell Line Development CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cell Line Development CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cell Line Development CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cell Line Development CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cell Line Development CDMO Market Size (2021-2032)
- 10.2 South America Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cell Line Development CDMO Market Size by Country (2021-2026)
- 10.4 South America Cell Line Development CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cell Line Development CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Cell Line Development CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cell Line Development CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cell Line Development CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Lonza
- 12.1.1 Lonza Company Information
- 12.1.2 Lonza Business Overview
- 12.1.3 Lonza Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.1.4 Lonza Cell Line Development CDMO Product Portfolio
- 12.1.5 Lonza Recent Developments
- 12.2 Samsung Biologics
- 12.2.1 Samsung Biologics Company Information
- 12.2.2 Samsung Biologics Business Overview
- 12.2.3 Samsung Biologics Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.2.4 Samsung Biologics Cell Line Development CDMO Product Portfolio
- 12.2.5 Samsung Biologics Recent Developments
- 12.3 AGC Biologics
- 12.3.1 AGC Biologics Company Information
- 12.3.2 AGC Biologics Business Overview
- 12.3.3 AGC Biologics Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.3.4 AGC Biologics Cell Line Development CDMO Product Portfolio
- 12.3.5 AGC Biologics Recent Developments
- 12.4 ProBio CDMO
- 12.4.1 ProBio CDMO Company Information
- 12.4.2 ProBio CDMO Business Overview
- 12.4.3 ProBio CDMO Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.4.4 ProBio CDMO Cell Line Development CDMO Product Portfolio
- 12.4.5 ProBio CDMO Recent Developments
- 12.5 Creative Biolabs
- 12.5.1 Creative Biolabs Company Information
- 12.5.2 Creative Biolabs Business Overview
- 12.5.3 Creative Biolabs Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.5.4 Creative Biolabs Cell Line Development CDMO Product Portfolio
- 12.5.5 Creative Biolabs Recent Developments
- 12.6 ProBioGen
- 12.6.1 ProBioGen Company Information
- 12.6.2 ProBioGen Business Overview
- 12.6.3 ProBioGen Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.6.4 ProBioGen Cell Line Development CDMO Product Portfolio
- 12.6.5 ProBioGen Recent Developments
- 12.7 InvivoGen
- 12.7.1 InvivoGen Company Information
- 12.7.2 InvivoGen Business Overview
- 12.7.3 InvivoGen Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.7.4 InvivoGen Cell Line Development CDMO Product Portfolio
- 12.7.5 InvivoGen Recent Developments
- 12.8 Eurofins Discovery
- 12.8.1 Eurofins Discovery Company Information
- 12.8.2 Eurofins Discovery Business Overview
- 12.8.3 Eurofins Discovery Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.8.4 Eurofins Discovery Cell Line Development CDMO Product Portfolio
- 12.8.5 Eurofins Discovery Recent Developments
- 12.9 Innoprot
- 12.9.1 Innoprot Company Information
- 12.9.2 Innoprot Business Overview
- 12.9.3 Innoprot Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.9.4 Innoprot Cell Line Development CDMO Product Portfolio
- 12.9.5 Innoprot Recent Developments
- 12.10 AcceGen
- 12.10.1 AcceGen Company Information
- 12.10.2 AcceGen Business Overview
- 12.10.3 AcceGen Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.10.4 AcceGen Cell Line Development CDMO Product Portfolio
- 12.10.5 AcceGen Recent Developments
- 12.11 WuXi Biologics
- 12.11.1 WuXi Biologics Company Information
- 12.11.2 WuXi Biologics Business Overview
- 12.11.3 WuXi Biologics Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.11.4 WuXi Biologics Cell Line Development CDMO Product Portfolio
- 12.11.5 WuXi Biologics Recent Developments
- 12.12 GenScript
- 12.12.1 GenScript Company Information
- 12.12.2 GenScript Business Overview
- 12.12.3 GenScript Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.12.4 GenScript Cell Line Development CDMO Product Portfolio
- 12.12.5 GenScript Recent Developments
- 12.13 Pharmaron
- 12.13.1 Pharmaron Company Information
- 12.13.2 Pharmaron Business Overview
- 12.13.3 Pharmaron Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.13.4 Pharmaron Cell Line Development CDMO Product Portfolio
- 12.13.5 Pharmaron Recent Developments
- 12.14 Bio-Inno
- 12.14.1 Bio-Inno Company Information
- 12.14.2 Bio-Inno Business Overview
- 12.14.3 Bio-Inno Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.14.4 Bio-Inno Cell Line Development CDMO Product Portfolio
- 12.14.5 Bio-Inno Recent Developments
- 12.15 Dingkang Biotech
- 12.15.1 Dingkang Biotech Company Information
- 12.15.2 Dingkang Biotech Business Overview
- 12.15.3 Dingkang Biotech Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.15.4 Dingkang Biotech Cell Line Development CDMO Product Portfolio
- 12.15.5 Dingkang Biotech Recent Developments
- 12.16 FUJIFILM
- 12.16.1 FUJIFILM Company Information
- 12.16.2 FUJIFILM Business Overview
- 12.16.3 FUJIFILM Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.16.4 FUJIFILM Cell Line Development CDMO Product Portfolio
- 12.16.5 FUJIFILM Recent Developments
- 12.17 JCR Pharmaceuticals
- 12.17.1 JCR Pharmaceuticals Company Information
- 12.17.2 JCR Pharmaceuticals Business Overview
- 12.17.3 JCR Pharmaceuticals Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.17.4 JCR Pharmaceuticals Cell Line Development CDMO Product Portfolio
- 12.17.5 JCR Pharmaceuticals Recent Developments
- 12.18 Sartorius
- 12.18.1 Sartorius Company Information
- 12.18.2 Sartorius Business Overview
- 12.18.3 Sartorius Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.18.4 Sartorius Cell Line Development CDMO Product Portfolio
- 12.18.5 Sartorius Recent Developments
- 12.19 Oxford BioMedica
- 12.19.1 Oxford BioMedica Company Information
- 12.19.2 Oxford BioMedica Business Overview
- 12.19.3 Oxford BioMedica Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.19.4 Oxford BioMedica Cell Line Development CDMO Product Portfolio
- 12.19.5 Oxford BioMedica Recent Developments
- 12.20 Cobra Biologics
- 12.20.1 Cobra Biologics Company Information
- 12.20.2 Cobra Biologics Business Overview
- 12.20.3 Cobra Biologics Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.20.4 Cobra Biologics Cell Line Development CDMO Product Portfolio
- 12.20.5 Cobra Biologics Recent Developments
- 12.21 Evotec
- 12.21.1 Evotec Company Information
- 12.21.2 Evotec Business Overview
- 12.21.3 Evotec Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.21.4 Evotec Cell Line Development CDMO Product Portfolio
- 12.21.5 Evotec Recent Developments
- 12.22 Catalent
- 12.22.1 Catalent Company Information
- 12.22.2 Catalent Business Overview
- 12.22.3 Catalent Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.22.4 Catalent Cell Line Development CDMO Product Portfolio
- 12.22.5 Catalent Recent Developments
- 12.23 Thermo Fisher Scientific
- 12.23.1 Thermo Fisher Scientific Company Information
- 12.23.2 Thermo Fisher Scientific Business Overview
- 12.23.3 Thermo Fisher Scientific Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.23.4 Thermo Fisher Scientific Cell Line Development CDMO Product Portfolio
- 12.23.5 Thermo Fisher Scientific Recent Developments
- 12.24 Cytiva
- 12.24.1 Cytiva Company Information
- 12.24.2 Cytiva Business Overview
- 12.24.3 Cytiva Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.24.4 Cytiva Cell Line Development CDMO Product Portfolio
- 12.24.5 Cytiva Recent Developments
- 12.25 Charles River Laboratories
- 12.25.1 Charles River Laboratories Company Information
- 12.25.2 Charles River Laboratories Business Overview
- 12.25.3 Charles River Laboratories Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.25.4 Charles River Laboratories Cell Line Development CDMO Product Portfolio
- 12.25.5 Charles River Laboratories Recent Developments
- 12.26 Abzena
- 12.26.1 Abzena Company Information
- 12.26.2 Abzena Business Overview
- 12.26.3 Abzena Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.26.4 Abzena Cell Line Development CDMO Product Portfolio
- 12.26.5 Abzena Recent Developments
- 12.27 Shilpa Biologicals
- 12.27.1 Shilpa Biologicals Company Information
- 12.27.2 Shilpa Biologicals Business Overview
- 12.27.3 Shilpa Biologicals Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.27.4 Shilpa Biologicals Cell Line Development CDMO Product Portfolio
- 12.27.5 Shilpa Biologicals Recent Developments
- 12.28 Teijin
- 12.28.1 Teijin Company Information
- 12.28.2 Teijin Business Overview
- 12.28.3 Teijin Revenue in Cell Line Development CDMO Business (2021-2026)
- 12.28.4 Teijin Cell Line Development CDMO Product Portfolio
- 12.28.5 Teijin Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst